Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2001, for DENTSPLY International Inc. (now DENTSPLY SIRONA Inc.). The Company is the world's largest designer, developer, manufacturer, and marketer of dental products, operating in a single reporting segment across over 120 countries. Its product lines are categorized into dental consumables and small equipment (90% of sales) and large equipment (7% of sales). The Company operates globally with significant exposure to foreign currency fluctuations, particularly in Europe.
Key Financial Metrics
Specific revenue, profit, and cash flow figures for the year ended December 31, 2001, are incorporated by reference to the 2001 Annual Report to Shareholders and are not explicitly detailed in the text of this filing. However, the following metrics are provided:
- Long-term Debt: $723.5 million as of December 31, 2001.
- Debt to Total Capitalization: 54.3%.
- Foreign Sales: Approximately 49% of consolidated net sales (up from 42% in 2000).
- Research and Development Investment: $28.3 million in 2001 (compared to $20.4 million in 2000 and $18.5 million in 1999).
- Market Capitalization: As of February 22, 2002, the aggregate market value of voting common stock held by non-affiliates was approximately $2.6 billion.
- Outstanding Shares: 77,924,485 shares as of February 22, 2002.
Material Changes and Acquisitions
The Company completed nine acquisitions between 1999 and 2001, with three significant transactions occurring in 2001:
- Friadent GmbH: Acquired in January 2001; a global dental implant manufacturer.
- AstraZeneca Assets: Acquired in March 2001; dental injectable anesthetic assets.
- Degussa Dental Group: Acquired in October 2001; a manufacturer of precious metal alloys, ceramics, and dental laboratory equipment.
These acquisitions increased the Company's presence in the European and Japanese markets and expanded its product breadth. Additionally, the Company eliminated approximately 310 administrative and manufacturing positions in Brazil and Germany in the first quarter of 2001 to improve efficiencies.
Outlook, Risks, and Management Commentary
Management Focus: The primary focus for 2002 is the integration of the 2001 acquisitions and the repayment of debt. The Company is investing in a new dental anesthetic filling plant outside Chicago, expected to be operational by the end of 2003.
Risks and Contingencies:
- Acquisition Integration: Risks include the inability to integrate operations efficiently, loss of key personnel, and unanticipated expenses.
- Debt Covenants: The Company's ability to service its debt depends on future performance. Breach of covenants could result in a default, allowing lenders to accelerate loan repayments.
- Legal Proceedings: The Company is involved in an antitrust investigation by the U.S. Department of Justice regarding the distribution of artificial teeth (Trubyte Division). While the Company believes the conduct does not violate antitrust laws, private class action suits remain pending.
- Regulatory: Products are subject to FDA and European Union regulations. There is ongoing public discussion regarding mercury in dental amalgam filling materials, though current regulatory bodies have not demonstrated direct hazards.
Investor Verification Checklist
- Verify the specific revenue, net income, and operating cash flow figures in the 2001 Annual Report to Shareholders, as they are incorporated by reference in this filing.
- Review the status of the antitrust litigation involving the Trubyte Division and the Department of Justice.
- Assess the progress of integration efforts for Friadent, AstraZeneca assets, and Degussa Dental, as these are critical to realizing anticipated benefits.
- Monitor compliance with debt covenants given the 54.3% debt-to-capitalization ratio and the focus on debt repayment in 2002.
- Check for updates on regulatory actions concerning dental amalgam and mercury content in various jurisdictions.